Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Total revenue	$ 14	$ 31	$ 93	$ 93
Operating expenses:
Research and development	558	1,665	2,160	4,321
Selling, general and administrative	8,269	2,721	17,239	7,640
Total operating expenses	8,827	4,386	19,399	11,961
Loss from operations	(8,813)	(4,355)	(19,306)	(11,868)
Non-cash change in fair value of convertible debentures	(3,697)	(22,571)	(28,180)	(24,890)
Change in fair value of warrant liability	1,349		1,349
Change in fair value of forward purchase put derivative	(1,284)		(1,284)
Change in fair value of forward purchase collateral derivative	(27,378)		(27,378)
Other expense	(779)	(2)	(883)	(31)
Interest expense	(424)	(313)	(1,250)	(825)
Total other expense	(32,213)	(22,886)	(57,626)	(25,746)
Loss before income taxes	(41,026)	(27,241)	(76,932)	(37,614)
Provision for income taxes
Net loss	$ (41,026)	$ (27,241)	$ (76,932)	$ (37,614)
Class A Common Stock
Operating expenses:
Net loss per common stock, basic and diluted (in Dollars per share)	$ (6.7)	$ (4.68)	$ (12.88)	$ (6.47)